Page 3 - Weight Loss

Novo Nordisk launches Wegovy in India to tackle obesity and heart risk

Wegovy is India's first weekly injectable approved for both long-term weight loss and reducing heart risks in obese and overweight adults

Novo Nordisk launches blockbuster weight-loss drug Wegovy in India

The 1.75 mg and 2.4 mg doses will be priced at ₹24,280, and 2.4 mg will be priced at ₹26,050 for a month

India's response to obesity drug Mounjaro 'positive', says Eli Lilly

Mounjaro has sold more than 81,570 units in India, totalling about ₹23.94 crore ($2.76 million) as of May, with the drug logging a 60 per cent rise in overall sales between April and May

Obesity injections may have less weight loss effect in reality: Study

Anti-obesity injections may have smaller effects on weight loss in a real-world context compared to clinical trials, as patients tend to discontinue treatment or use a lower maintenance dose, a study in US patients has found. Semaglutide, sold under the brand names Wegovy and Ozempic, and tirzepatide (Zepbound and Mounjaro) are prescribed for weight management and treating type 2 diabetes by helping patients regulate blood sugar. The study, published in the Obesity Journal, examined the effects of anti-obesity injectables on weight reduction and blood sugar regulation (glycaemic control) in a real-world setting. "Our study shows that patients treated for obesity with semaglutide or tirzepatide lost less weight on average in a regular clinical setting compared to what is observed in randomised clinical trials," lead author Dr Hamlet Gasoyan, a researcher with the Cleveland Clinic, US, said. "According to our data, this could be explained by higher rates of discontinuation and lower

New mechanism rewires cell energy processing for weight loss, shows study

Led by researchers at NYU Grossman School of Medicine, the study reveals key details about how cells process fuels like carbohydrates and fats, and how cysteine depletion affects tissues

Lilly's obesity drug Mounjaro's sales rise 60% in India amid rising demand

The US drugmaker sold ₹12.6 crore ($1.5 million) worth of the injections last month, according to market analysis firm Pharmarack Technologies

Why Ozempic maker Novo Nordisk is losing its lead in weight-loss drugs

The Danish drugmaker led the obesity revolution with Ozempic and Wegovy but now lags Eli Lilly in efficacy, trials, and strategy in a $150-bn market

Novo Nordisk to launch weight-loss drug Wegovy in India ahead of schedule

Amid rising demand and Eli Lilly's Mounjaro launch, Novo Nordisk is advancing plans to introduce its obesity drug Wegovy in the Indian market

Ozempic teeth, face and tongue: Side effects of GLP-1 drugs explained

As the use of weight-loss injections rises, users report effects like Ozempic face, tongue, and teeth- here is what these mean and how to manage them

What happens to your weight after stopping Ozempic, Wegovy or Mounjaro?

Many people using GLP-1 weight-loss drugs like Ozempic, Wegovy or Mounjaro regain the weight after stopping- experts explain why it happens, who's at risk, and how to keep the weight off

Eli Lilly's tirzepatide shows superior weight loss to Novo's semaglutide

Phase 3b trial finds Lilly's tirzepatide delivers higher average weight loss and waist reduction than Novo's semaglutide in people with obesity or overweight

Mounjaro helps users lose more weight than Wegovy, new trial reveals

GLP-1 drug Zepbound leads to greater weight and waist loss than Wegovy in 72-week trial, say researchers at European Congress on Obesity comparing new-generation weight-loss drugs

Can weight-loss drugs like Ozempic help prevent cancer? New study says yes

New research suggests GLP-1 drugs like Ozempic, Wegovy, Mounjaro may lower the risk of several obesity-related cancers, even matching surgery in preventive benefits

US judge denies injunction, restricts copies of weight-loss drug Ozempic

A US judge earlier barred compounders from making copies of Eli Lilly's Zepbound and Mounjaro

Eli Lilly's first weight-loss pill shows success in initial Phase 3 trials

Lilly CEO says if approved, drug could be manufactured and launched at scale globally

Why Mounjaro's India entry has doctors and patients picking up the phone

With obesity on the rise, Eli Lilly's weight-loss injection triggers a rush of consultations as Indians seek safer, cheaper options to black-market drugs

Kapil Sharma stuns internet with sleek new look ahead of film sequel

Kapil Sharma, who is gearing up for the sequel to Kis Kisko Pyaar Karoon, left fans stunned with his dramatic weight loss. Social media is abuzz, calling it the 'best example of hard work'

Mumbai-based start-up launches probiotic combo for weight management

Co claims that the formulation naturally increases GLP-1 levels and regulates appetite

Weight-loss drug Mounjaro now available in India: All you need to know

Mounjaro, Eli Lilly's diabetes and obesity drug, is now available in India at a fraction of its US price. It offers treatment for weight loss and diabetes control, but watch out for the side effects

Herbalife faces challenge from homegrown Modiway in weight-loss mkt

To put into perspective, the weight-loss market is big and, according to industry estimates, it hit $25 billion in 2024, and is expected to expand to $55 billion by 2033